The
founder of XPD Consulting, Dr. Andrew Parkinson, has over 25 years of academic
experience and over 16 years of industrial experience in the area of in vitro drug metabolism and safety
testing
Dr. Andrew Parkinson was a full-time faculty member at the University of Kansas Medical
Center from 1987 to 1999.
Since 1999 he has
held an adjunct professorship of pharmacology and toxicology at KUMC
Dr. Andrew Parkinson founded XenoTech, a contract research organization specializing in in vitro drug metabolism and safety
testing. He served as CEO and/or CSO until 2011
Dr. Andrew Parkinson has consulted for over 100 pharmaceutical clients and written over 75 Expert Opinions for clients in North America, Europe and Japan
Brandy Paris worked for XenoTech from 1998
to 2011. Her positions included Head of Drug Inhibition, Executive Consultant
and Chief Operating Officer
Dr. Oliver Parkinson worked for XenoTech and for Dr. Elizabeth Gillam at the University of Queensland, Australia before he entered graduate school at the University of Washington in Seattle,
where his Ph.D. advisor was Professor Allan Rettie
Today, at XPD Consulting, Dr. Andrew
Parkinson serves as CEO, Brandy Paris as President, and Dr. Oliver Parkinson as Consultant.
